home All News open_in_new Full Article
Ipilimumab N01 Plus Sintilimab Earns NMPA Approval in China for Resectable MSI
today 2 w. ago attach_file Politics
attach_file
Politics
attach_file
Economics
attach_file
Politics
attach_file
Politics
attach_file
Events
attach_file
Politics
attach_file
Politics
attach_file
Politics
attach_file
Events
attach_file
Events
attach_file
Events
attach_file
Politics
attach_file
Politics
attach_file
Politics
attach_file
Politics
attach_file
Politics
attach_file
Politics
ID: 938415682